Description: Eli Lilly and Co (LLY) is a member of the S&P 500, a Dividend Aristocrat and a member of the Broad Dividend Achievers™ Index. The company discovers, develops, manufactures and sells prescription drugs that offers a wide range of treatments for neurological disorders, diabetes, cancer, and other conditions. The company also sells animal health products.
Quantitative Stock Analysis: Updated: 5-16-2009
Comments: Updated: 5-16-2009
Like all pharmaceutical companies, LLY faces generic challenges to the its branded patents. The company must continuously development new drugs and face regulatory risks. LLY has a robust pipeline and a diverse drug portfolio with limited near-term patent expirations. Risks include competitive pressures and failure of new drugs to perform.